Research ArticleArticle
In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity
Johan Monbaliu, Martha Gonzalez, Apexa Bernard, James Jiao, Carlo Sensenhauser, Jan Snoeys, Hans Stieltjes, Inneke Wynant, Johan W. Smit and Caly Chien
Drug Metabolism and Disposition October 2016, 44 (10) 1682-1691; DOI: https://doi.org/10.1124/dmd.116.070672
Johan Monbaliu
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Martha Gonzalez
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Apexa Bernard
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
James Jiao
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Carlo Sensenhauser
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Jan Snoeys
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Hans Stieltjes
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Inneke Wynant
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Johan W. Smit
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Caly Chien
Janssen Research & Development, Preclinical Project Development (J.M.), Bioanalysis (H.St.), Pharmacokinetics, Dynamics and Metabolism (J.S, I.W.), and Clinical Pharmacology, (H.Sm.), Beerse, Belgium; Janssen Research & Development, Clinical Pharmacology (M.G., A.B.) and Biometrics and Reporting (J.J.), Raritan, New Jersey; Janssen Research & Development, Pharmacokinetics, Dynamics and Metabolism (C.S.), Spring House, Pennsylvania; Janssen Research & Development, Clinical Pharmacology (C.C.), Titusville, New Jersey
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Drug-Drug Interaction Studies of Abiraterone and CYP2C8
Johan Monbaliu, Martha Gonzalez, Apexa Bernard, James Jiao, Carlo Sensenhauser, Jan Snoeys, Hans Stieltjes, Inneke Wynant, Johan W. Smit and Caly Chien
Drug Metabolism and Disposition October 1, 2016, 44 (10) 1682-1691; DOI: https://doi.org/10.1124/dmd.116.070672
Research ArticleArticle
Drug-Drug Interaction Studies of Abiraterone and CYP2C8
Johan Monbaliu, Martha Gonzalez, Apexa Bernard, James Jiao, Carlo Sensenhauser, Jan Snoeys, Hans Stieltjes, Inneke Wynant, Johan W. Smit and Caly Chien
Drug Metabolism and Disposition October 1, 2016, 44 (10) 1682-1691; DOI: https://doi.org/10.1124/dmd.116.070672
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement